Explore

Merck and Moderna's Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence by 42% in Trial

Merck and Moderna's Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence by 42% in Trial

A personalized mRNA cancer vaccine, developed by Merck and Moderna, has demonstrated a 42% reduction in the risk of melanoma recurrence or death when combined with the immunotherapy drug Keytruda, compared to Keytruda alone. This experimental treatment, known as intismeran autogene, is a therapeutic vaccine tailored for individual patients with an existing cancer diagnosis. It functions by analyzing a tumor sample to identify genetic mutations that produce abnormal proteins (neoantigens) and then creating an mRNA treatment to stimulate an immune response against these specific cancer cell characteristics. The Phase 3 INTerpath-001 clinical trial involved over 1,100 high-risk melanoma patients whose tumors had been surgically removed. After a median follow-up of 24.6 months, the combination therapy also reduced the relative risk of cancer spreading to distant parts of the body or death by 38%. The detailed findings were announced on October 22, 2026, as part of the European Society for Medical Oncology (ESM...

Immuto Scientific to Present Novel Drug Target Data for Colorectal Cancer and AML at Upcoming Conferences

Immuto Scientific to Present Novel Drug Target Data for Colorectal Cancer and AML at Upcoming Conferences

Immuto Scientific, an AI-enabled therapeutics company, announced it will present structural surfaceomics data on novel drug targets for colorectal cancer (CRC) and acute myeloid leukemia (AML) at two upcoming conferences: the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics and the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. At ENA 2026, Immuto will present research from its collaboration with the University of Wisconsin-Madison, focusing on identifying new target opportunities in patient-derived RAS colorectal cancer models. At ASH 2026, the company will present preclinical data on IMTO-4842.1, a mutation-agnostic antibody-drug conjugate (ADC) targeting an AML-specific surface protein conformer. These presentations aim to demonstrate how Immuto's structural surfaceomics platform uncovers disease-specific targets defined by changes in protein structure on the cell surface.

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Resolution Therapeutics Presents Positive Interim Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease

Resolution Therapeutics Presents Positive Interim Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease

Resolution Therapeutics has announced positive interim six-month data from its Phase I/II EMERALD trial, which is evaluating RTX001, an investigational autologous engineered regenerative macrophage therapy (RMT). The trial focuses on patients suffering from end-stage liver disease (ESLD). The data indicates a signal of efficacy in clinical outcomes such as death, liver transplant, and hepatic decompensation. RTX001 was well tolerated by patients, with no serious adverse reactions related to infusion and no severe adverse events attributed to the treatment. Furthermore, prospectively defined biomarkers showed reductions in inflammation and fibrogenesis markers, aligning with the predicted mechanism of regenerative macrophages. The company plans to discuss the program with the FDA and advance RTX001 towards a planned U.S. pivotal trial. These findings will be presented at The Liver Meeting 2026 of the American Association for the Study of Liver Diseases (AASLD) in Denver, Colorado.

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Onchilles Pharma Reports Promising Early Clinical Data for N17350, a Personalized Cancer Vaccine Approach

Onchilles Pharma Reports Promising Early Clinical Data for N17350, a Personalized Cancer Vaccine Approach

Onchilles Pharma, a clinical-stage biotechnology company, has reported initial clinical findings from its Phase 1/2 trial (OP-NEU-101) of intratumoral N17350 in patients with advanced solid tumors. The data, presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), suggest that N17350 could effectively turn an injected tumor into a personalized cancer vaccine without requiring tumor sequencing or custom manufacturing. N17350 is an engineered therapeutic elastase derived from a cancer-killing enzyme found in human neutrophils. When injected into a tumor, it selectively kills cancer cells and releases the tumor's own antigens, thereby training the immune system to attack cancer elsewhere in the body. In the first dose cohort, three heavily pretreated patients showed no dose-limiting toxicities. Notably, a patient with Merkel cell carcinoma experienced the disappearance of five non-injected lesions after N17350 was injected into a single lesion, indicating systemic immune activat...

Oncopeptides to Present New European Real-World Evidence for Pepaxti in Multiple Myeloma at ASH 2026

Oncopeptides to Present New European Real-World Evidence for Pepaxti in Multiple Myeloma at ASH 2026

Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, has announced that two abstracts detailing real-world clinical outcomes for its drug Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting. The meeting is scheduled to take place in New Orleans, USA, from December 12–15, 2026. These abstracts are based on two independent multicenter retrospective studies conducted in Spain and Italy, involving a total of 82 heavily pretreated RRMM patients. The studies aim to reinforce the clinical utility and manageable safety profile of Pepaxti when used in combination with dexamethasone in real-world European clinical practice. This includes its application in patients who have previously received T-cell-redirecting immunotherapies, such as anti-BCMA and anti-GPRC5D agents, and as a bridging therapy between immunotherapies.

Indapta Therapeutics Presents Positive Clinical Data for IDP-023 in Multiple Myeloma at SITC Annual Meeting

Indapta Therapeutics Presents Positive Clinical Data for IDP-023 in Multiple Myeloma at SITC Annual Meeting

Indapta Therapeutics, a privately held clinical-stage biotechnology company, announced an oral presentation of positive Phase 1 clinical data for its IDP-023 allogeneic g-NK cell therapy. The data, presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix, Arizona, showcased the therapy's efficacy and safety in combination with isatuximab for heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Key findings include a 45% overall response rate and a 6.3-month median progression-free survival in daratumumab-refractory patients. Notably, one patient with ultra-high-risk disease and extensive prior treatments achieved a stringent complete response lasting over a year. The treatment was generally well-tolerated, with no dose-limiting toxicities or significant adverse events like cytokine release syndrome.

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics, a California-based biotech company, has released preliminary clinical data for its gene-edited sickle cell disease (SCD) therapy, nula-cel. The data, to be presented at the American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three patients. These patients have also demonstrated restored expression of adult hemoglobin (HbA) and have become transfusion-independent, experiencing no pain crises since receiving their gene-edited hematopoietic stem cells (HSCs). Unlike FDA-approved Casgevy, which increases fetal hemoglobin (HbF), Kamau's nula-cel therapy directly replaces the SCD mutation using homology-directed repair (HDR). The company reports that sickle hemoglobin (HbS) levels fell below 20% of total hemoglobin in two patients who reached the 6-month post-infusion mark. The Phase I/II RESTORE trial is currently enrolling 15 participants.

Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer

Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer

Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer

Antengene Initiates Phase I ATTRACT Study for Autoimmune Disease Treatment ATG-201 in China and Australia

Antengene Initiates Phase I ATTRACT Study for Autoimmune Disease Treatment ATG-201 in China and Australia

Antengene Corporation Limited, a global biotech company, has announced that the first patient has been dosed in China for its Phase I ATTRACT study. This study evaluates ATG-201, Antengene's proprietary CD19 × CD3 bispecific T-cell engager antibody (TCE), in adult patients suffering from B cell-mediated autoimmune diseases. The study is being conducted in both China and Australia, with ATG-201 having received approval from the Human Research Ethics Committee (HREC) in Australia and completing the Clinical Trial Notification (CTN) process with the Therapeutic Goods Administration (TGA). ATG-201 is designed to precisely target and eliminate CD19-expressing B cells using steric hindrance masking technology, aiming to leverage the body's immune system for treating these diseases. The ATTRACT study, led by Professor Zhanguo Li, will assess the safety, tolerability, and preliminary efficacy of ATG-201 in two parts: Dose Escalation (Part I) and Dose Expansion (Part II).